Pharmacy Point-of-Sale (POS)
Pharmacy PA (applies to prescription drugs typically dispensed by outpatient pharmacies – (click here for instructions)
Gainwell Technologies handles PA requests for drugs billed through the POS venue. If you are a Mississippi Medicaid prescriber, please submit your PA requests through the Gainwell provider web portal (preferred route) or fax completed PA forms to the number below. The phone number for the Gainwell Pharmacy PA Unit is also listed below.
Toll-free: | 833-660-2402 |
Fax: | 866-644-6147 |
Universal Preferred Drug List (UPDL) – Click here to access the UPDL.
Non-preferred drugs require PA review for approval. Some preferred products may require PA as indicated on the UPDL.
Other Drugs Requiring PA – Many drugs are covered by Medicaid but are not listed on the UPDL. Click here for a list of drugs not listed on the UPDL that require PA.
Such requests should be submitted using a Universal PA Form.
Select the appropriate PA packet from the drop-down menus below when requesting a PA.
Prior Authorization Packets
Prior Authorization Packets | Updated |
---|---|
Anti-Obesity Select Agents | 7/1/2024 |
Brand Name Multi-Source | 7/1/2024 |
Early Refill | 7/1/2024 |
Enteral Nutrition | 7/1/2024 |
EPSDT – Beneficiaries Under 21 | 7/1/2024 |
Growth Hormone | 7/1/2024 |
Hepatitis C Therapy | 7/1/2024 |
Max Unit Override | 7/1/2024 |
Multiple Concurrent Antipsychotics for Beneficiaries (Age < 18) | 7/1/2024 |
Opioid Packet – Effective 8/1/2019 FAQs | 10/1/2024 |
PDL Exception Request | 7/1/2024 |
RSV-SYNAGIS® | 10/15/2024 |
Universal Prior Authorization Form | 7/1/2024 |
Manual PA Criteria
Manual Prior Authorization Criteria | Updated |
---|---|
Adbry Atopic Dermatitis | 11/8/2022 |
Akynzeo | 2/3/2020 |
Antipsychotics | 2/3/2020 |
Austedo | 1/10/2024 |
CGRPs | 7/1/2024 |
Corlanor | 2/3/2020 |
Cresemba | 2/3/2020 |
Dalvance | 12/18/2024 |
Dupixent – Asthma | 2/3/2020 |
Dupixent – Atopic Dermatitis | 12/18/2024 |
Dupixent – Eosinophilic Esophagitis | 3/1/2024 |
Dupixent – Nasal Polyposis | 12/27/2021 |
Dupixent – Prurigo nodularis | 11/7/2022 |
Elevidys | 7/12/2024 |
Emflaza | 4/28/2022 |
Endari | 2/3/2020 |
Eucrisa | 4/1/2020 |
Evrysdi | 1/10/2024 |
Exondys | 2/3/2020 |
Farydak | 2/3/2020 |
Fasenra | 3/3/2023 |
Hemlibra | 2/3/2020 |
Imcivree | 2/1/2024 |
Ingrezza | 1/10/2024 |
Jadenu | 2/3/2020 |
Juxtapid | 2/3/2020 |
Kalydeco | 1/27/2021 |
Lotronex | 2/3/2020 |
Lynparza | 6/3/2020 |
Mavenclad | 2/3/2020 |
Mayzent | 2/3/2020 |
Ocrevus | 10/21/2024 |
Orkambi | 2/3/2020 |
Palforzia | 12/16/2020 |
Praluent | 9/12/2023 |
Probuphine | 2/3/2020 |
Repatha | 9/12/2023 |
Sivextro | 2/3/2020 |
Stribild | 2/3/2020 |
Sublocade | 2/3/2020 |
Symdeko | 1/27/2021 |
Trikafta | 7/9/2021 |
Tybost | 2/3/2020 |
Varubi | 2/3/2020 |
Viltepso | 1/21/2021 |
Vivitrol | 2/3/2020 |
Vyepti | 2/10/2021 |
Vyjuvek | 10/27/2023 |
Vyondys 53 | 1/22/2021 |
Xolair – Asthma | 1/1/2023 |
Xolair – Nasal Polyps | 1/1/2023 |
Xolair – Urticaria | 1/1/2023 |
Zontivity | 2/3/2020 |
Zurzuvae | 4/1/2024 |
Zyvox | 2/3/2020 |
Physician-Administered Drug (PAD) Prior Authorization Instructions
Telligen handles requests for drugs billed on medical claims for fee-for-service members. Please click here to search the Telligen prior authorization portal.
Miscellaneous Forms
Pharmacy Reconsideration Request Form